MedTrace Logo

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants

NCT06868082 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-02-09

No results posted yet for this study

Summary

A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Formulations of Subcutaneously Administered Solrikitug in Healthy Japanese and non-Japanese Participants

Conditions

  • Healthy

Interventions

BIOLOGICAL

Solrikitug

Solrikitug Formulation 1

BIOLOGICAL

Solrikitug

Solrikitug Formulation 2

Sponsors & Collaborators

  • Uniquity One (UNI)

    lead INDUSTRY

Principal Investigators

  • Andrew Lee, MD · Uniquity One

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-20
Primary Completion
2026-02-02
Completion
2026-02-02
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06868082 on ClinicalTrials.gov